EPCAM and cholangiocarcinoma: For detection of CCA-derived CTCs, EpCAM appears to be a valid marker since the majority of CCAs express EpCAM [114] although only 10–20% of these patients display an upregulation of EpCAM levels, when compared with non-tumoral tissue [115], therefore limiting the applicability of this platform for CCA.